TLR2 and neoplasm: The results showed that unmatched tumor antigen rlipo-OVA-MoGM therapy had no impact on TC-1 tumor growth in either treated tumors or distal tumors, indicating that the antitumor efficacy induced by the combination of the TLR2 agonist and GM-CSF was tumor antigen dependent (figure 3D, E).